The world market of aesthetics found colors. While the crisis had fall by 15 in 2009, it increased by 10 last year, to EUR 3.5 billion, according to figures provided by the Imcas World Observatory of the sector, including the annual Conference is held until Sunday in Paris. The sales of different products (filling, lasers, botulinum toxin, breast implants, etc.) remains less than the 3.8 billion euros in 2008.
The Palm of the growth is the wrinkle. Filling such as hyaluronic acid products and long-term injectable substances indeed show an increase of 13, to EUR 520 million. In France, the increase reached even 20, 25 million. Next comes the botulinum toxin, which eliminates wrinkles in immobilizing the muscles, including the famous of Allergan Botox and Dysport of Ipsen, sold in the United States by Medicis and Europe by Galderma. If the market is improved by 11 last year at the global level, it is mainly the European Outlook with optimism: a leap of 25 per year is expected to here to 2014 of EUR 285 million. Because the European market is still young, compared to the United States, where the botulinum toxin must culminate in 414 million in three years.
Lasers in the blur
"In Europe, the market of toxins exceed products of filling in 2014, with the arrival of a third product in the market and a broader communication on the part of the labs." "By contrast, in the United States, the strongest growth will return to filling products, which offer will increase, resulting in a decline in prices," says Laurent Brones, responsible for the development in Symatese Biomaterials.
The recovery is more uncertain in the field of equipment (lasers, lights, radio frequency and ultrasound) energy-based, which is still lower for a third level of 2008. "Periods of great boom of the rejuvenation, the spots or the rosacea treatments are completed." "Machines Park stagnates and physicians think twice before investing between 50,000 and 100,000 euros in new equipment," analysis Benjamin Ascher, founder and Scientific Director of the Imcas.
Overall, the trend remains turned towards less invasive than surgery techniques. And if the placement of breast implants is the first practised Act, its prospects for progress are limited to 4 per year in Europe by 2014, compared to 11 for all aesthetic sectors. "Breast prostheses, the liposuction and the textbook remain safe values because there is no alternative treatment." But the practice, more natural, outweighs the US key. "It's the end of the"too much"caricature of the West Coast", moderate Benjamin Ascher. The ideal would be to obtain with creams of results comparable to those obtained with injections of botulinum toxin or acid. It is the bet of the Californian Revance, botulinum toxin cream is in the last phase of clinical trials.
The growth of the market will also from emerging countries, including the Brazil, second market aesthetics after the United States, and Asia, where the American Syneron is poised to launch Elure, a skin whitening product.
Proof of the attractiveness of the sector, it attracts more in addition to "big pharma", such as Johnson & Johnson or Bayer. Intendis, its activity in dermatology, the German giant is currently studying the possibilities of the désoxycholine, an injectable product against the fat of the double chins.
The myth of the single room is still strongSince the launch of the euro is possibleHowever the propensity to distribution is not without riskThey have benefited to some than to othersA local vote local issue pounding on the UMPAdolescent touchy and solitary he have never known the casually or frivolity Sarkozy accused Juppe of having lied to himFinally one is out of the lot it is VodafoneDisabled this barrier to the most urgent Because the restructuring will take time
